Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | GD2-CART01 |
Synonyms | |
Therapy Description |
GD2-CART01 comprises T-lymphocytes engineered to express a chimeric antigen receptor (CAR) that targets GD2 and contains CD28 and TNFRSF9 (4-1BB) costimulatory domains, along with inducible Caspase-9, which potentially induces cytotoxicity against GD2-expressing tumor cells and inhibits tumor growth (PMID: 29872565) |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
GD2-CART01 | iC9-GD2-CAR T-cells | GD2-CART01 comprises T-lymphocytes engineered to express a chimeric antigen receptor (CAR) that targets GD2 and contains CD28 and TNFRSF9 (4-1BB) costimulatory domains, along with inducible Caspase-9, which potentially induces cytotoxicity against GD2-expressing tumor cells and inhibits tumor growth (PMID: 29872565) |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03373097 | Phase Ib/II | GD2-CART01 | Anti-GD2 CAR T Cells in Pediatric Patients Affected by High Risk and/or Relapsed/Refractory Neuroblastoma or Other GD2-positive Solid Tumors | Recruiting | ITA | 0 |
NCT05298995 | Phase I | GD2-CART01 | GD2-CAR T Cells for Pediatric Brain Tumours | Recruiting | ITA | 0 |